SGLT2 Inhibitor Selection and Dosing for Impaired Renal Function

Agent Selection Based on eGFR

For patients with type 2 diabetes and impaired renal function, the American College of Cardiology recommends initiating an SGLT2 inhibitor at eGFR ≥20 mL/min/1.73 m² and continuing treatment even if eGFR subsequently falls below this threshold, as cardiovascular and kidney benefits persist independent of glucose-lowering effects 1, 2
For patients with eGFR ≥45 mL/min/1.73 m², the American College of Cardiology recommends empagliflozin 10 mg once daily, canagliflozin 100 mg once daily, or dapagliflozin 10 mg once daily, as all three agents have equivalent efficacy in this range 3
For patients with eGFR 30-44 mL/min/1.73 m², canagliflozin 100 mg once daily or dapagliflozin 10 mg once daily are recommended, while empagliflozin is not recommended for initiation in this range per FDA labeling 3, 4

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend continuing SGLT2 inhibitors even if eGFR falls below initiation thresholds, unless dialysis is started or the medication is not tolerated, as the cardiovascular and kidney protective benefits persist at lower eGFR levels despite reduced glucose-lowering efficacy 1, 2, 6
A reversible decrease in eGFR of up to 30% within 4 weeks of initiation is expected and is not an indication to discontinue therapy, representing hemodynamic changes from reduced glomerular hyperfiltration, not kidney injury 1, 6

Before initiating SGLT2 inhibitors, assess volume status and correct hypovolemia, consider reducing thiazide or loop diuretic doses to prevent volume depletion, and verify normal serum potassium if planning combination with RAS inhibitors 1, 2, 6

For patients with albuminuria ≥200 mg/g (≥20 mg/mmol), SGLT2 inhibitors are strongly recommended regardless of diabetes status when eGFR ≥20 mL/min/1.73 m², representing a Class 1A recommendation from KDIGO 2024 1, 2
SGLT2 inhibitors should be combined with maximum tolerated RAS inhibitor therapy in patients with diabetes and CKD, and can be safely added to metformin (if eGFR ≥30 mL/min/1.73 m²) without dose adjustment of other agents unless hypoglycemia risk exists 4, 6, 7